Results from the post-exposure prophylaxis pilot program (P-QUAD) demonstration project in Los Angeles County

Int J STD AIDS. 2018 May;29(6):557-562. doi: 10.1177/0956462417743158. Epub 2017 Nov 29.

Abstract

Post-exposure prophylaxis (PEP) is a promising but under-utilized strategy for HIV prevention in high-risk populations. Between March 2010 and June 2011, two community-based clinics in Los Angeles County provided PEP in a pilot program to 267 unique individuals. Courses were primarily dispensed to men who have sex with men (84%) and consisted overwhelmingly of a three-drug antiretroviral therapy regimen containing two nucleoside reverse transcriptase inhibitors and either an integrase inhibitor (raltegravir) or a boosted protease inhibitor (lopinavir/ritonavir). Approximately 64% of all PEP courses were followed for at least 12 weeks, and seven individuals seroconverted. Of the seven seroconversions, six had subsequent re-exposure. The low rate of PEP failure calls for expanded funding for PEP in other jurisdictions.

Keywords: Antiretroviral therapy; HIV; North America; high-risk behavior; homosexual.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Adolescent
  • Adult
  • Anti-HIV Agents / administration & dosage*
  • Female
  • HIV Infections / drug therapy
  • HIV Infections / prevention & control*
  • HIV-1 / drug effects*
  • Homosexuality, Male*
  • Humans
  • Lopinavir / administration & dosage
  • Los Angeles
  • Male
  • Medication Adherence / psychology*
  • Middle Aged
  • Pilot Projects
  • Post-Exposure Prophylaxis / methods*
  • Raltegravir Potassium / administration & dosage
  • Reverse Transcriptase Inhibitors / administration & dosage*
  • Ritonavir / administration & dosage
  • Young Adult

Substances

  • Anti-HIV Agents
  • Reverse Transcriptase Inhibitors
  • Lopinavir
  • Raltegravir Potassium
  • Ritonavir